%D9%81%D8%A7%D9%81%D9%8A%D8%A8%D9%8A%D8%B1%D8%A7%D9%81%D9%8A%D8%B1%E0%A6%AB%E0%A6%BE%E0%A6%AD%E0%A6%BF%E0%A6%AA%E0%A6%BF%E0%A6%B0%E0%A6%BE%E0%A6%AD%E0%A7%80%E0%A6%B0FavipiravirFavipiravirFavipiravirFavipiravirFavipiravirFavipiraviir%D9%81%D8%A7%D9%88%DB%8C%D9%BE%DB%8C%D8%B1%D8%A7%D9%88%DB%8C%D8%B1Favipiravir%D7%A4%D7%91%D7%99%D7%A4%D7%99%D7%A8%D7%91%D7%99%D7%A8FavipiravirFavipiravir%E3%83%95%E3%82%A1%E3%83%93%E3%83%94%E3%83%A9%E3%83%93%E3%83%AB%ED%8C%8C%EB%B9%84%ED%94%BC%EB%9D%BC%EB%B9%84%EB%A5%B4FavipiravirasFavipiravirFawipirawirFavipiravir%D0%A4%D0%B0%D0%B2%D0%B8%D0%BF%D0%B8%D1%80%D0%B0%D0%B2%D0%B8%D1%80FavipiravirFavipiravir%E0%B8%9F%E0%B8%B2%E0%B8%A7%E0%B8%B4%E0%B8%9E%E0%B8%B4%E0%B8%A3%E0%B8%B2%E0%B9%80%E0%B8%A7%E0%B8%B5%E0%B8%A2%E0%B8%A3%E0%B9%8CFavipiravir%D0%A4%D0%B0%D0%B2%D1%96%D0%BF%D1%96%D1%80%D0%B0%D0%B2%D1%96%D1%80FavipiravirQ16934561%E6%B3%95%E5%8C%B9%E6%8B%89%E9%9F%A6
about
P2176
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymeraseBroad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley FeverT-705 (favipiravir) inhibition of arenavirus replication in cell cultureEvaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic feverIn Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsEfficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodentsActivity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106Effect of T-705 treatment on western equine encephalitis in a mouse modelRole of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirinEffective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic FeverFavipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic feverExperimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaAntiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.Favipiravir: a new medication for the Ebola virus disease pandemic.T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitroEfficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome VirusModeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with FavipiravirEffects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.T-705 (favipiravir) activity against lethal H5N1 influenza A virusesPost-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease modelsFavipiravir (T-705) inhibits in vitro norovirus replication.Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells.Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir.Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen.Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses
P921
Q21089768-dff2ea43-4a8c-7cb2-a9d3-ee00955107c9Q21092271-F2F4D442-5462-49FD-B768-416C8AF39AB6Q24633241-3083E344-BA0C-4D60-B326-0D04A4AE7361Q27457152-2127BC07-D959-40E4-99F4-157D70441077Q27481401-BCD48968-2262-4FE8-8665-811ABCD128EEQ27487357-276A9BFC-38CB-4C48-8B88-DC86A082D3EDQ27487527-F1CD668B-859B-48CA-93EF-E55877B2B0CFQ27488864-24655DA2-4BD6-454B-9628-EA208DF2D60FQ27685318-2F39A5D4-0843-45FC-A78C-22606394335BQ28474006-D54B53EC-37AB-4E7D-8148-C661CCEA7ACCQ28477434-D3E7762F-429F-442E-BFFC-E0A939C237E4Q28537976-1739A6B6-4BB7-4BBD-8694-A3FDAFA2791CQ28550455-d74eae1c-47f3-3401-5f7a-135b279ef1c3Q30151965-3692B73E-4203-4967-BA3E-328CF83CD0D1Q30356466-6765FA25-ACFB-425C-A8AD-81C25DD096E6Q30359363-353E2450-DC41-4B4A-AAF9-D7385B67F8FAQ30364319-4DE162D2-1273-435D-A952-D01B3043BE44Q30370190-2195d13f-48af-7b74-be22-811ec111d97fQ30376917-551C6D83-C003-4234-9A6B-3C1A58C99409Q30387420-A145BF25-DB6B-46C1-9C3B-1DC8556B4B18Q30414428-4DCCFACE-8BF0-4958-BE83-A6320DEFAE9DQ30426020-6E1BC0FE-A2F1-4849-989F-59EDD7F22FB9Q33433096-F9472BDF-80CB-4895-81BE-5D7633D88640Q33437038-283DC9D0-D6A9-4A3C-A5E8-33002FFF4452Q33559151-CDB85F0C-0A32-4E95-8205-E0A3B088C1A4Q33639979-9FEDE8BC-E86E-40C0-B89D-5B14082EBA1AQ34039673-13B49A0A-E606-47AD-A07C-4944E16A361DQ34040021-229885DB-4A25-440F-9E55-1A87A5D41AF4Q34374652-03D43198-4B6C-47E4-967C-86361359BDB3Q34432483-1C055B8D-3804-45F5-847D-19B69463A517Q34640499-FE83D3A2-7253-48B5-A1D3-BE6A3BACA3B9Q34994834-3FA459DC-51D0-4C4A-82E4-1B1C31AE9910Q35624775-2F5D7A6E-DCBD-4B0C-B8D9-88EEAC79EF38Q35647695-25079AE1-6607-42EE-AF4D-67DD8085BFCFQ35952190-7E071124-04B1-48B8-9F58-20CC1794EC80Q36146469-9D0342E2-2D6C-4B55-BFA3-7BC433AA082BQ36166222-34363E02-5B7C-4B40-829B-C164D1D881BCQ36243643-CBA79C22-DAA0-4D72-944E-3482571E0698Q36288297-BF321819-A7CC-4E2C-8B6B-F287E74BE2BBQ36494323-8E2D3E95-4B87-444C-91A9-C56DAE6FC0E3
P921
description
Favipiravir kimyasal bileşik
@tr
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Favipiraviir
@et
Favipiravir
@cs
Favipiravir
@de
Favipiravir
@id
Favipiravir
@nl
Favipiravir
@si
Favipiravir
@sv
Favipiravir
@tr
Favipiravir
@vi
Favipiraviras
@lt
type
label
Favipiraviir
@et
Favipiravir
@cs
Favipiravir
@de
Favipiravir
@id
Favipiravir
@nl
Favipiravir
@si
Favipiravir
@sv
Favipiravir
@tr
Favipiravir
@vi
Favipiraviras
@lt
altLabel
5-fluoro-2-hydroxypyrazine-3-carboxamide
@en
Avigan
@it
Avigan
@tr
T-705
@en
T-705
@pl
T-705
@uk
favilavir
@en
Авиган
@ru
Авифавир
@ru
Авіган
@uk
prefLabel
Favipiraviir
@et
Favipiravir
@cs
Favipiravir
@de
Favipiravir
@id
Favipiravir
@nl
Favipiravir
@si
Favipiravir
@sv
Favipiravir
@tr
Favipiravir
@vi
Favipiraviras
@lt
P592
P6366
P661
P662
P683
P117
P2067
P231
259793-96-9
P233
C1=C(N=C(C(=O)N1)C(=O)N)F
P234
1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
P235
ZCGNOVWYSGBHAU-UHFFFAOYSA-N
P274
P3117
DTXSID60948878
P592
CHEMBL221722
P6366
2779772310
P652
EW5GL2X7E0